Bio-Rad Laboratories, Inc. (BIO) Shares Sold by Alliancebernstein L.P.

Alliancebernstein L.P. lowered its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 2.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 328,388 shares of the medical research company’s stock after selling 6,809 shares during the period. Alliancebernstein L.P. owned about 1.11% of Bio-Rad Laboratories worth $74,317,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of BIO. Oregon Public Employees Retirement Fund increased its position in shares of Bio-Rad Laboratories by 1.4% during the first quarter. Oregon Public Employees Retirement Fund now owns 7,225 shares of the medical research company’s stock worth $1,440,000 after purchasing an additional 100 shares in the last quarter. Great West Life Assurance Co. Can increased its position in shares of Bio-Rad Laboratories by 3.9% during the first quarter. Great West Life Assurance Co. Can now owns 12,380 shares of the medical research company’s stock worth $2,467,000 after purchasing an additional 469 shares in the last quarter. State Board of Administration of Florida Retirement System increased its position in shares of Bio-Rad Laboratories by 4.5% during the first quarter. State Board of Administration of Florida Retirement System now owns 31,359 shares of the medical research company’s stock worth $6,251,000 after purchasing an additional 1,362 shares in the last quarter. First Trust Advisors LP increased its position in shares of Bio-Rad Laboratories by 738.2% during the first quarter. First Trust Advisors LP now owns 24,935 shares of the medical research company’s stock worth $4,971,000 after purchasing an additional 21,960 shares in the last quarter. Finally, Flinton Capital Management LLC increased its position in shares of Bio-Rad Laboratories by 17.6% during the first quarter. Flinton Capital Management LLC now owns 640 shares of the medical research company’s stock worth $128,000 after purchasing an additional 96 shares in the last quarter. Institutional investors and hedge funds own 62.85% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was originally published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://transcriptdaily.com/2017/09/13/bio-rad-laboratories-inc-bio-shares-sold-by-alliancebernstein-l-p.html.

Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) opened at 218.04 on Wednesday. Bio-Rad Laboratories, Inc. has a 52-week low of $154.89 and a 52-week high of $242.79. The firm has a market cap of $6.46 billion, a PE ratio of 430.91 and a beta of 0.93. The stock’s 50 day moving average price is $222.70 and its 200-day moving average price is $216.60.

In other news, EVP Michael Crowley sold 700 shares of the company’s stock in a transaction dated Friday, August 11th. The shares were sold at an average price of $215.91, for a total value of $151,137.00. Following the sale, the executive vice president now owns 2,060 shares in the company, valued at approximately $444,774.60. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 28.29% of the company’s stock.

A number of analysts have recently commented on BIO shares. Jefferies Group LLC reiterated a “buy” rating and set a $275.00 target price on shares of Bio-Rad Laboratories in a research report on Friday, July 14th. Deutsche Bank AG upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating and cut their target price for the stock from $220.00 to $195.00 in a research report on Wednesday, June 28th. BidaskClub upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday, June 22nd. TheStreet cut Bio-Rad Laboratories from a “b” rating to a “c+” rating in a research report on Thursday, August 3rd. Finally, Zacks Investment Research cut Bio-Rad Laboratories from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 5th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. Bio-Rad Laboratories has an average rating of “Buy” and an average price target of $228.80.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply